10/19/2005 5:09:04 PM
BOSTON--(BUSINESS WIRE)--Aug. 1, 2005--CureLab, Inc. a biotech company with offices in Massachusetts and California, today announced that it has been awarded a grant from the National Institute of Health (NIH) to continue its development work towards a vaccine against the influenza (flu) virus.
CureLab has developed patent pending, proprietary technology that it believes will enable it to develop a vaccine that would be effective against all strains of the flu virus, both known and unknown. This award from the NIH is the first phase of a two-phase grant under the Small Business Innovation Research (SBIR) Bio Defense Program. CureLab expects that the total amount of this award will be seven million dollars.
comments powered by